Beckman Coulter, Inc. introduces Solastra, a comprehensive CE-marked panel of conjugated-antibody cocktails for the characterization of hematolymphoid neoplasia by flow cytometry.
Despite FDA approval, it remains to be seen how frequently Provenge will be used in castration-resistant prostate cancer (CRPC), according to a Datamonitor analyst.
CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California-based contract research and development organization, have signed of a strategic license agreement.
Covidien announced that its Mallinckrodt Baker business unit has entered into a multi-year agreement with global laboratory supply company, VWR International, LLC, to distribute Mallinckrodt Baker’s J.T.Baker brand products in Eastern and Central Europe.
Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled.
Abbott announced that the U.S. Food and Drug Administration approved once-daily dosing of Kaletra for adult patients with HIV who have previously taken antiretroviral therapy.
A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval, offering an important alternative to more taxing treatments like chemotherapy.
The Justice Department says Schwarz Pharma Inc. will pay $22 million for allegedly failing to disclose that two of its products did not qualify for federal health care coverage.
United Therapeutics Corp.'s first-quarter profit increased 43 percent after the Food and Drug Administration approved two of its blood pressure drugs.
Drugmaker Bristol-Myers Squibb Co. reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel due to the impact of the health care overhaul.
Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced.
Three top drugmakers have posted healthy increases in first-quarter sales and profits, with strong sales of key drugs buoying Bristol-Myers Squibb Co., AstraZeneca LP and Sanofi-Aventis SA.
The next time Stephen Quake is prescribed a drug, he says he won't worry about having a bad reaction. The Stanford University professor will simply consult his genome to see if there are any warning signs in his DNA.